Most drugmakers fulfill post-marketing pledges; Court upholds patent on Shire's Vyvanse;

@FiercePharma: Feds charge former GSK exec with off-label cover-up. Article | Follow @FiercePharma

> Most makers of approved drug and biological products are meeting their regulatory obligations and meeting targets for postmarketing studies and clinical trials in a timely manner, according to a study released by the FDA. FDA release

> Shire says a U.S. appeals court has upheld the exclusivity of its attention deficit hyperactivity drug Vyvanse, keeping cheaper generic versions off the market until February 2012. Shire release | Report

> Shares in Swiss biotech Actelion pushed as much as 2.5 percent higher after renewed talk the company could be the next takeover target in the biopharmaceuticals industry. Article

> Forest Laboratories says President and Chief Operating Officer Lawrence Olanoff will retire Dec. 31. Forest release | Story

> Few teenage girls and young women are getting the human papillomavirus vaccine, and many of those who start the regimen fail to take all three doses, new research reveals. News

> Ranbaxy Laboratories, India's largest drugmaker, says third-quarter profit more than doubled, helped by sales of a generic version of GlaxoSmithKline's herpes medicine Valtrex and foreign exchange gains. Ranbaxy release | Report

> Nycomed has seen its sales inch downwards in the third quarter, as the decline of its biggest seller pantoprazole continued. Nycomed release | Article

> Stada Arzneimittel reported a third-quarter loss after some Serbian pharmaceutical wholesalers failed to pay the German generic-drug maker. Stada release | Item

> Somaxon Pharmaceuticals' third-quarter net loss widened as the company rang up expenses for the launch of its insomnia drug Silenor. Somaxon release | Story

> The FDA approved Egrifta, the first drug designed specifically to treat lipodystrophy in HIV-positive patients undergoing antiretroviral therapy, to be marketed in the U.S. by EMD Serono. Theratechnologies release | Report

Biotech News

 @FierceBiotech: GSK: Expect more M&A deals and new collaborative enterprises. News | Follow @FierceBiotech

 @JohnCFierce: Second take on Arena: Looks pretty bleak for any quick OK. The CEO keeps digging deeper and deeper, though. Is his job on the line? Follow @JohnCFierce

> Roche's sidelined programs could be used to launch new biotechs. News 

> Novartis writes off $120M and the once-promising ASA404. Report 

> Clovis extends deal-making spree with $206M Asian pact. Story 

> VCs inject $29M into Syntaxin, $11.5M into Ceregene. Article 

Vaccines News

> Discovery could show why cancer vaccines have failed. Story 

> BiondVax looks to make mark in universal flu vax space. News 

> Nasal delivery: the future of the flu vax. Report 

> A look at the late-stage vaccine pipeline. Article 

> Aaron Diamond team working on HIV vax. Item 

Manufacturing News

> FDA again defends response to tainted heparin. Story 

> Group calls on FDA for objective Tylenol investigation. Item 

> At Genzyme, Thyrogen, Cerezyme production rises. Report 

> Ingestible smart-pill sensor will relay patient data. Article 

> Puerto Rico tax shows drugmakers the door. News 

> Indiana aims to recycle pharma layoff victims. Story

And Finally... When consumers pay $4 cash for a prescription, there's no incentive for pharmacies to go through the hassle of submitting the claim, skewing data on prescription drug use. Report